SG11202008921YA - Micro-rna and obesity - Google Patents

Micro-rna and obesity

Info

Publication number
SG11202008921YA
SG11202008921YA SG11202008921YA SG11202008921YA SG11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA
Authority
SG
Singapore
Prior art keywords
obesity
rna
micro
Prior art date
Application number
SG11202008921YA
Inventor
Pier Paulo Pandolfi
Riccardo Panella
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of SG11202008921YA publication Critical patent/SG11202008921YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity
SG11202008921YA 2018-03-14 2019-03-14 Micro-rna and obesity SG11202008921YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862642934P 2018-03-14 2018-03-14
PCT/US2019/022350 WO2019178410A1 (en) 2018-03-14 2019-03-14 Micro-rna and obesity

Publications (1)

Publication Number Publication Date
SG11202008921YA true SG11202008921YA (en) 2020-10-29

Family

ID=67908026

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202008921YA SG11202008921YA (en) 2018-03-14 2019-03-14 Micro-rna and obesity
SG11202008925VA SG11202008925VA (en) 2018-03-14 2019-03-14 Inhibitors of micro-rna 22

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202008925VA SG11202008925VA (en) 2018-03-14 2019-03-14 Inhibitors of micro-rna 22

Country Status (11)

Country Link
US (2) US11499152B2 (en)
EP (2) EP3765619A4 (en)
JP (2) JP2021518841A (en)
KR (2) KR20200132920A (en)
CN (2) CN112119159A (en)
AU (2) AU2019234916A1 (en)
BR (2) BR112020018705A2 (en)
CA (2) CA3093572A1 (en)
RU (2) RU2020132725A (en)
SG (2) SG11202008921YA (en)
WO (2) WO2019178410A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018705A2 (en) 2018-03-14 2021-01-05 Beth Israel Deaconess Medical Center MICROWAVE INHIBITORS 22
CN110609142A (en) * 2019-10-09 2019-12-24 广州医科大学附属第二医院 Method for detecting binding capacity of peripheral blood FTO protein and self-regulation element and application
CN115029347B (en) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 Molecular monitoring sequence for recognizing and regulating hepatic and renal cell fibrosis, recombinant plasmid and virus inhibition
EP4353823A1 (en) * 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
AU731909B2 (en) 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
SK17432000A3 (en) 1998-05-26 2001-07-10 Icn Pharmaceuticals, Inc. Novel nucleosides having bicyclic sugar moiety
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
JP4868739B2 (en) 2002-05-06 2012-02-01 アルナイラム ファーマシューティカルズ, インコーポレイテッド Nucleic acid delivery methods
DK2302055T3 (en) * 2004-11-12 2014-10-13 Asuragen Inc Methods and compositions involving miRNA and miRNA inhibitor molecules
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
JP2009519339A (en) * 2005-12-12 2009-05-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル MicroRNAs that regulate myocyte proliferation and differentiation
AU2013254923A1 (en) * 2006-04-03 2013-11-28 Santaris Pharma A/S Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
ES2463665T3 (en) * 2007-10-04 2014-05-28 Stella Aps Combination treatment for the treatment of hepatitis C virus infection
WO2010120803A2 (en) * 2009-04-13 2010-10-21 Somagenics Inc. Methods and compositions for detection of small rnas
NZ597078A (en) * 2009-06-08 2013-11-29 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
UY33807A (en) * 2010-12-17 2012-07-31 Sanofi Sa miRNAs as indicators of tissue status or of diseases such as osteoarthritis
CA2832899A1 (en) 2011-04-12 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Micro-rna inhibitors and their uses in disease
WO2013125691A1 (en) * 2012-02-23 2013-08-29 住友ベークライト株式会社 Method for classifying test body fluid sample
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
WO2013181613A1 (en) * 2012-05-31 2013-12-05 Research Development Foundation Mirna for the diagnosis and treatment of autoimmune and inflammatory disease
WO2013192576A2 (en) * 2012-06-21 2013-12-27 Miragen Therapeutics Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9822358B2 (en) * 2013-10-18 2017-11-21 Beth Israel Deaconess Medical Center Treatment of cancers with micro-RNA inhibitors
CA2935426C (en) * 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
US20180042847A1 (en) * 2015-03-16 2018-02-15 Duncan ROSS Method of treatment comprising membrane-enclosed vesicle
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN107432933A (en) * 2017-07-13 2017-12-05 中南大学湘雅三医院 Applications of the miR 22 as target site in the chemotherapy sensitizing medicine for preparing carcinoma of urinary bladder
WO2019053235A1 (en) * 2017-09-15 2019-03-21 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
BR112020018705A2 (en) 2018-03-14 2021-01-05 Beth Israel Deaconess Medical Center MICROWAVE INHIBITORS 22
WO2019217907A1 (en) * 2018-05-11 2019-11-14 The Regents Of The University Of California Methods and compositions for the treatment of hepatic and metabolic diseases

Also Published As

Publication number Publication date
RU2020131372A (en) 2022-04-14
CA3093572A1 (en) 2019-09-19
US20210017520A1 (en) 2021-01-21
JP2021518841A (en) 2021-08-05
US20210017521A1 (en) 2021-01-21
CN111918968B (en) 2023-11-24
EP3765610A4 (en) 2022-01-19
AU2019234917A1 (en) 2020-10-01
CN112119159A (en) 2020-12-22
BR112020018752A2 (en) 2021-01-05
CA3093844A1 (en) 2019-09-19
KR20200132920A (en) 2020-11-25
EP3765619A4 (en) 2021-12-08
JP7318166B2 (en) 2023-08-01
US11753639B2 (en) 2023-09-12
JP2021518159A (en) 2021-08-02
SG11202008925VA (en) 2020-10-29
RU2020132725A (en) 2022-04-15
WO2019178410A1 (en) 2019-09-19
KR20200131287A (en) 2020-11-23
EP3765619A1 (en) 2021-01-20
US11499152B2 (en) 2022-11-15
BR112020018705A2 (en) 2021-01-05
EP3765610A1 (en) 2021-01-20
AU2019234916A1 (en) 2020-10-15
CN111918968A (en) 2020-11-10
WO2019178411A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
IL275737A (en) Antibodies and variants thereof against tigit
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
SG11202008921YA (en) Micro-rna and obesity
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
IL278832A (en) Optimized gp41-binding molecules and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
IL276807A (en) Modified plyss2 lysins and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
IL283926A (en) Anti-alpha-synuclein antibodies and uses thereof
GB201812561D0 (en) Biomarkers and uses thereof
IL283890A (en) Anti-periostin antibodies and uses thereof
GB201806042D0 (en) Biomarkers and uses thereof
IL275211A (en) Fast and partition-resilient blockchains
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL280369A (en) New myokines and uses thereof